View all newsletters
Keeping a pulse on activities around innovations in Pharma sector is the key ingredient in informing strategies and making key business decisions. Corroborating signals from various business activities and further deducing key performance indicators, creates a 360Β° view around whoβs and whatβs of sector relevant innovations.
In partnership with
The trendline shows the deals activity related to the innovation by month for this industry. The count represents the number of deals in the last completed 12 months.
The trendline shows the granted patent activity by month for this industry. The count represents the number of patents that were granted in the last completed 12 months.
Research and innovation in fintech in the clinical trial operations sector has stagnated in the last quarter. The most recent figures show that the number of fintech related patent applications in the industry stood at...
Research and innovation in robotics in the clinical trial operations sector has declined in the last year. The most recent figures show that the number of robotics related patent applications in the industry stood at...
Innovations applied for IP protection tracks new noteworthy patent applications published recently in the Pharma Sector including ground-breaking technologies and the companyβs technological and strategic shift towards adoption of new technologies.
ModernaTX, Inc. has been issued a patent which is important for the COVID-19 vaccine technology. The claimed mRNA vaccine encodes highly immunogenic antigens that elicit potent neutralizing antibodies against coronavirus antigens, which βsurprisinglyβ share less than 80 percent identity with the antigen sequences of Severe Acute Respiratory Syndrome (SARS), another disease caused by a strain of coronavirus.
An independent inventor Patrick M. Nemechek of Buckeye, AZ has been issued a patent which is directed at a method for preventing, reducing or reversing cytokine storm, a severe immune system response caused by COVID-19 that can devastate tissues and organs within a patient suffering from the disease. Method includes administering vagus nerve stimulation. Stimulation of the vagus nerve has been shown to reduce inflammation.
Eisai R&D Management Co Ltd and Harvard College has been issued a patent which provides novel Compound having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt. The compound can be used for treating cancer or inhibiting tumor growth.
GlobalDataΒ captures news, deals, filings, jobs, patents, and social media signals etc. and gathers the activities around innovation-led initiatives supported in the respective organisations. Our analysis suggests that Johnson & Johnson has been most upfront in adopting emerging technologies amongst its peers.
Data from March 2017 onwards
Note: GlobalData captures various data sets such as deals, filings, jobs, patents. Each data set score is combined (π₯π πππππ) to provide an overall weighted-average exposure score. The scores are then used to show the colours on the heat map and represent the level of exposure in which a darker shade represents higher levels of exposure while a lighter shade represents lower levels of exposure. Each cell in any respective column indicates the relative Company Investment Intensity of the ten tech themes compared across the list of companies for that theme.
| Themes | Deal Value(US$m) |
|---|---|
| Artificial Intelligence | 54,010.0 |
| Big Data | 16,670.4 |
| Cloud | 7,714.4 |
| Robotics | 4,810.2 |
| Internet of Things | 3,526.4 |
| 3D Printing | 999.7 |
| Blockchain | 400.9 |
| Virtual and Augmented Reality | 38.0 |
The sectorial representation of the Pharma sector based on growth in patenting activity and number of deals show, Oncology as the emerging therapy area/indications. Having less patent records, Solid Tumor, marks presence as the innovation therapy area/indications with highest growth in patenting activity and deal size.
Data from March 2017 onwards
Note: Bubble size represents the number of deals for that sector during the past five years.
|
Therapy area/ Indications |
No of Deals |
|---|---|
| Oncology | 14,023 |
| Solid Tumor | 3,387 |
| Breast Cancer | 3,183 |
| Pain | 2,728 |
| Diabetes | 2,683 |
| Inflammation | 1,359 |
| Ocular Inflammation | 584 |
